The current global state of health, the threat of the SARS-2-COVID-19 virus, is a concern to many.

The best way to deal with this situation is to avoid getting very sick, avoid exposure as much as possible, and prepare the body to fight the virus in the best way possible because everybody will get exposed eventually in one way or another. For those people who choose not to get vaccinated, this becomes even more important and urgent.

The medical and epidemiological community is trying to find correlations and strategies on how to reduce serious manifestations and death in COVID-19 patients, including activating natural biological pathways(1).


Glutathione quotes:

  • … glutathione deficiency is the most plausible explanation for serious manifestation and death in COVID-19 patients was proposed on the basis of an exhaustive literature analysis and observations.(2)
  • … the ability of glutathione (GSH) to inhibit viral replication and decrease levels of IL-6 in human immunodeficiency virus (HIV) and tuberculosis (TB) patients, as well as beneficial effects of GSH on other pulmonary diseases processes, we believe the use of GSH could be beneficial in COVID-19 patients.(3)
  • … evidence from literature that demonstrates the reduced levels of GSH in the main conditions clinically associated with severe disease, we highlight the relevance of restoring GSH levels in the attempt to protect the most vulnerable subjects from severe symptoms of COVID-19.(4)
Carnosine quotes:
  • … carnosine has promising inhibitory interactions with host ACE2 and nCoV spike protein and hence could offer a potential mitigating effect against the current COVID-19 pandemic.(5)
  • … carnosine could protect against some of the detrimental effects of SARS-CoV-2 infection.(6)
  • … carnosine is an effective anti-inflammatory agent which can also inhibit CD26 and ACE2 activity.(7)

1. Peter A. McCullough, MD, MPH et al., Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection, The American Journal of Medicine, Vol 134, No 1, January 2021
2. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients, Alexey Polonikov, ACS Infect. Dis. 2020, 6, 7, 1558–1562
Glutathione Supplementation as an Adjunctive Therapy in COVID-19, Vika Guloyan et al., Antioxidants 2020, 9, 914
The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19, Francesca Silvagno et al., Antioxidants 2020, 9, 624
Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein, Loai M. Saadah et al., Molecules 2020, 25, 5605
Nutritional Interventions for COVID-19: A Role for Carnosine? Jack Feehan et al., Nutrients 2021, 13, 1463
7. COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine? Alan R. Hipkiss, Aging and Disease • Volume 11, Number 4, August 2020